3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
1
Gastrointestinal
1
Conditions
Glioblastoma
40
Carcinoma, Non-Small-Cell Lung
22
Head and Neck Neoplasms
20
Brain Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
11
Glioma
11
Lung Neoplasms
8
Carcinoma, Squamous Cell
8
Breast Neoplasms
8
Astrocytoma
8
Rectal Neoplasms
7
Neoplasms
7
Prostatic Neoplasms
6
Mucositis
5
Esophageal Neoplasms
5
Carcinoma
4
Neoplasm Metastasis
3
Esophageal Squamous Cell Carcinoma
3
Colorectal Neoplasms
3
Xerostomia
2
Stomatitis
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Neoplasms, Squamous Cell
2
Lymphoma
2
Leukemia
2
Laryngeal Diseases
2
Gliosarcoma
2
Adenocarcinoma Of Esophagus
2
Adenocarcinoma
2
Interventions
pembrolizumab
180
Cisplatin
44
Paclitaxel
41
Carboplatin
41
lenvatinib
31
Docetaxel
22
Pemetrexed
20
Fluorouracil
19
Capecitabine
16
Gemcitabine
15
Saline Solution
13
Oxaliplatin
13
Albumin-Bound Paclitaxel
10
epacadostat
9
130-nm albumin-bound paclitaxel
9
Leucovorin
8
Cetuximab
8
olaparib
7
Irinotecan
7
Bevacizumab
7
Etoposide
6
belzutifan
5
Dexamethasone
5
enzalutamide
4
trifluridine tipiracil drug combination
3
regorafenib
3
patritumab deruxtecan
3
enfortumab vedotin
3
durvalumab
3
Surgical Procedures, Operative
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Radiotherapy
×
Clear all
NCT04210115
2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
703 enrolled
NCT03040999
2026-02-04
KEYNOTE-412
Merck Sharp & Dohme LLC
Phase 3
Completed
804 enrolled
20 charts